Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07531043 Apraclonidine Hydrochloride Eye Redness Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07531043 Apraclonidine Hydrochloride Eye Redness Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07531043 clinical trial report covering Apraclonidine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261443 Benzoyl Peroxide/Tretinoin Acne Vulgaris Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261443 Benzoyl Peroxide/Tretinoin Acne Vulgaris Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261443 clinical trial report covering Benzoyl Peroxide/Tretinoin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07533123 JSKN016 Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07533123 JSKN016 Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07533123 clinical trial report covering JSKN016, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600122711 Teplizumab Diabetes Mellitus, Type 1 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600122711 Teplizumab Diabetes Mellitus, Type 1 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600122711 clinical trial report covering Teplizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07533175 Zenagamtide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07533175 Zenagamtide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07533175 clinical trial report covering Zenagamtide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07533747 Empagliflozin Coronary microvascular dysfunction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07533747 Empagliflozin Coronary microvascular dysfunction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07533747 clinical trial report covering Empagliflozin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261249 Compound Caraway Enteric Liquid Capsule Abdominal Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261249 Compound Caraway Enteric Liquid Capsule Abdominal Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261249 clinical trial report covering Compound Caraway Enteric Liquid Capsule, Phase 3, endpoints, sponsor, geography, readout timing and development
Read →
CTR20261254 Compound Caraway Enteric Liquid Capsule Abdominal Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261254 Compound Caraway Enteric Liquid Capsule Abdominal Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261254 clinical trial report covering Compound Caraway Enteric Liquid Capsule, Phase 3, endpoints, sponsor, geography, readout timing and development
Read →
NCT07537933 Tirofiban Hydrochloride Vascular occlusive disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07537933 Tirofiban Hydrochloride Vascular occlusive disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07537933 clinical trial report covering Tirofiban Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07536373 Colchicine Chronic Limb-Threatening Ischemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07536373 Colchicine Chronic Limb-Threatening Ischemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07536373 clinical trial report covering Colchicine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
JPRN-jRCT2011260002 Ramantamig Refractory Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2011260002 Ramantamig Refractory Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
JPRN-jRCT2011260002 clinical trial report covering Ramantamig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07536763 Drospirenone/Estetrol Contraception Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07536763 Drospirenone/Estetrol Contraception Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07536763 clinical trial report covering Drospirenone/Estetrol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →